Sanj K Patel, Chairman and CEO of Kiniksa Pharmaceuticals International, plc, filed a Form 4 on November 6, 2026, disclosing the exercise of 145,763 stock options and the sale of 151,300 Class A Ordinary Shares on November 4, 2026, all under a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Patel exercised 145,763 fully vested share options at an exercise price of $17.92 per share on November 4, 2026, through The Anglia 2013 Revocable Trust.
  • Shares sold: A total of 151,300 Class A Ordinary Shares were disposed of across five separate sale transactions on November 4, 2026, all held indirectly through The Anglia 2013 Revocable Trust.
  • Sale prices: The weighted average sale prices across the five transactions were $92.35, $93.54, $94.20, $95.48, and $96.05 per share, with individual trades ranging as high as $96.19.
  • Remaining indirect holdings: Following the reported transactions, Patel beneficially owned 774,500 Class A Ordinary Shares through The Anglia 2013 Revocable Trust, 92,348 through The Patel Family Irrevocable Trust of 2025, and 109,795 through The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016.
  • 10b5-1 plan: According to the filing, all transactions were effected pursuant to a 10b5-1 plan executed by Patel on July 30, 2026.
  • Derivative position closed: Following the option exercise, the number of share options beneficially owned directly by Patel dropped to 0, per the filing.

Patel's November 4 Option Exercise and Share Sales at Kiniksa Pharmaceuticals

According to the Form 4 filed with the SEC on November 6, 2026, Sanj K Patel, who serves as Chairman and CEO of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA), exercised 145,763 share options at $17.92 per share on November 4, 2026. The filing indicates the option was fully vested and had an expiration date of March 3, 2029. The exercise added 145,763 Class A Ordinary Shares to the holdings of The Anglia 2013 Revocable Trust, an entity through which Patel holds shares indirectly.

On the same date, the filing discloses that 151,300 Class A Ordinary Shares were sold across five transactions, all from The Anglia 2013 Revocable Trust. The five disposals were: 1,460 shares at a weighted average price of $92.35 (individual trade range $91.945-$92.655); 11,335 shares at $93.54 (range $92.95-$93.92); 81,742 shares at $94.20 (range $93.95-$94.94); 29,845 shares at $95.48 (range $94.95-$95.94); and 26,918 shares at $96.05 (range $95.95-$96.19). Each of these sales was executed in multiple trades through a broker-dealer, and the filing states that weighted average prices are reported, with full per-price detail available to SEC staff upon request.

After all reported transactions, the filing shows Patel indirectly holds 774,500 Class A Ordinary Shares through The Anglia 2013 Revocable Trust, 92,348 shares through The Patel Family Irrevocable Trust of 2025, and 109,795 shares through The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016. The filing was signed by Douglas Barry as Attorney-in-Fact on November 6, 2026, and the transactions are noted as having been made pursuant to a 10b5-1 plan executed on July 30, 2026.

What Was Disclosed

The Form 4 discloses that Kiniksa's Chairman and CEO Sanj K Patel exercised 145,763 share options at $17.92 and sold 151,300 Class A Ordinary Shares at weighted average prices between $92.35 and $96.05 on November 4, 2026, all pursuant to a pre-established 10b5-1 plan.